Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 6c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.75), $0.06 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $7.23 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Cerebras Q1 EPS miss sends shares down 9% after-hours